StockNews.com began coverage on shares of Amarin (NASDAQ:AMRN - Free Report) in a research note issued to investors on Wednesday. The firm issued a sell rating on the biopharmaceutical company's stock.
Amarin Stock Down 2.7 %
Amarin stock traded down $0.25 on Wednesday, hitting $9.11. The company's stock had a trading volume of 115,140 shares, compared to its average volume of 72,778. Amarin has a one year low of $7.08 and a one year high of $20.60. The firm has a market cap of $187.06 million, a P/E ratio of -101.22 and a beta of 1.38. The company has a fifty day moving average price of $9.78 and a 200-day moving average price of $10.43.
Amarin (NASDAQ:AMRN - Get Free Report) last posted its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($1.20). The business had revenue of $62.31 million during the quarter, compared to analyst estimates of $32.37 million. Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. Analysts anticipate that Amarin will post -0.15 EPS for the current year.
Institutional Trading of Amarin
Several institutional investors have recently bought and sold shares of AMRN. Waterfront Wealth Inc. lifted its holdings in shares of Amarin by 181.4% during the fourth quarter. Waterfront Wealth Inc. now owns 2,481,766 shares of the biopharmaceutical company's stock valued at $1,204,000 after acquiring an additional 1,599,956 shares during the period. AXA S.A. acquired a new stake in shares of Amarin during the 4th quarter worth about $480,000. Raymond James Financial Inc. bought a new position in Amarin during the 4th quarter valued at about $343,000. Quinn Opportunity Partners LLC boosted its position in Amarin by 85.2% in the fourth quarter. Quinn Opportunity Partners LLC now owns 1,106,539 shares of the biopharmaceutical company's stock valued at $537,000 after buying an additional 508,989 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Amarin during the fourth quarter worth about $171,000. Institutional investors and hedge funds own 22.25% of the company's stock.
About Amarin
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Further Reading
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
